-
Recent Posts
Recent Comments
- MichaelOrdman on Fighting over Israeli engineers
- Elaine Morales on Fighting over Israeli engineers
- MichaelOrdman on Enriched seaweed can feed the world
- Professor Rajan Rajan on Enriched seaweed can feed the world
- MichaelOrdman on Fast glaucoma treatment in trials
Archives
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- July 2010
Categories
Meta
Search Results for: Enlivex
Treatment for knee osteoarthritis
Denmark’s Medicines Agency has approved Allocetra cell therapy from Israel’s Enlivex (see here previously) for Phase II clinical trials on patients with osteoarthritis in the knee. 40% of men and 47% of women develop knee osteoarthritis in their lifetimes. Allocetra … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Cancer therapy that could change the world
Allocetra from Israel’s Enlivex (see here previously) saved many patients suffering from Covid-19 and sepsis. Clinical trials have now begun, using it to treat patients with advanced solid tumors. Allocetra reprograms immune system macrophages that cause cancer. https://www.jpost.com/jerusalem-report/article-713192 https://enlivex.com/investor-relations/#latest-news
Posted in Israel's Medical Achievements
Leave a comment
Innovations in Life Sciences
On 2nd Mar, the JNF is hosting a webinar featuring Israeli and US innovations in the Life Sciences. It includes the Chief Scientific & Medical Officer Prof. Dror Mevorach of Israel’s Enlivex Therapeutics – developer of COVID-19 “cure” Allocetra. Registration … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Good Phase 2 results of Covid-19 treatment
Allocetra from Israel’s Enlivex Therapeutics (reported here previously) has cured the majority of the 37 seriously and critically ill Covid-19 patients in its Phase 1b and 2 trials. 33 patients were discharged from hospital an average of under 6 days … Continue reading
Posted in Israel's Medical Achievements
Leave a comment
Five patients saved by new Covid-19 treatment
Israel’s Enlivex Therapeutics reported positive results in its clinical Covid-19 trial of its Allocetra treatment (reported here previously) Five seriously ill patients made complete recoveries, an average 8.5 days after receiving the treatment.at Jerusalem’s Hadassah hospital. https://www.jpost.com/israel-news/5-patients-leave-hadassah-coronavirus-free-after-clinical-trial-644071 https://www.calcalistech.com/ctech/articles/0,7340,L-3852110,00.html
Posted in Israel's Medical Achievements
Leave a comment
Treatment for severe victims of coronavirus
As reported previously, (see here) the Allocetra treatment from Israel’s Enlivex cures patients suffering severe sepsis. Allocetra is now being offered to governments for the thousands of coronavirus patients suffering sepsis-induced organ failure due to overactive immune responses. https://www.jpost.com/HEALTH-SCIENCE/Israeli-company-ready-to-assist-coronavirus-victims-with-novel-drug-617777
Posted in Israel's Medical Achievements
Leave a comment
Good results in sepsis treatment trial
As reported previously (see here) Israel’s Enlivex Therapeutics has developed Allocetra which rebalances the immune system. Allocetra was given to six patients suffering from severe sepsis at Hadassah hospital in Jerusalem. All survived. http://www.xinhuanet.com/english/2019-11/04/c_138528152.htm
Posted in Israel's Medical Achievements
Leave a comment
Israeli bio-techs merge
I reported previously (see here) on Jerusalem-based immunotherapy company Enlivex Therapeutics. Enlivex has merged with Tel Aviv-headquartered Bioblast (see here), which is developing treatments for rare genetic diseases. https://www.calcalistech.com/ctech/articles/0,7340,L-3759270,00.html
Posted in Israel's Medical Achievements
Leave a comment
Funds for immunotherapy treatment
I reported previously (three times) on Israel’s Enlivex and its Allocetra / Apocell treatment to prevent Graft vs Host Disease – a common problem after bone marrow transplants. Elivex has just received $8 million of funding which will help it … Continue reading
Posted in Economy & Business
Leave a comment
Bone marrow treatment gets boost
In January I mentioned Apocell from Israeli biotech Enlivex, which prevents GVHD rejection of bone marrow transplants. Now, the treatment has received US FDA “orphan” status due to its importance and lack of alternatives for treating the unwanted autoimmune response. … Continue reading
Posted in Israel's Medical Achievements
Leave a comment